Primary sclerosing cholangitis and cholangiocarcinoma:the 2023 practice guidance and future perspectives  

作　　者：Francesca Saffioti Vasileios K.Mavroeidis 

机构地区：[1]Department of Gastroenterology and Hepatology,Oxford University Hospitals NHS Foundation Trust,John Radcliffe Hospital,Oxford,UK [2]UCL Institute for Liver and Digestive Health,University College London,London,UK [3]Department of HPB Surgery,University Hospitals Bristol&Weston NHS Foundation Trust,Bristol Royal Infirmary,Bristol,UK [4]Department of Transplant Surgery,North Bristol NHS Trust,Southmead Hospital,Bristol,UK

出　　处：《Hepatobiliary Surgery and Nutrition》2024年第1期172-175,共4页肝胆外科与营养（英文）

摘　　要：The 2023 practice guidance on primary sclerosing cholangitis(PSC)and cholangiocarcinoma(CCA)of the American Association for the Study of Liver Diseases(AASLD)came as a needful update to the previous 2010 guidelines on PSC,with a first-time inclusion of dedicated guidance on the diagnosis and management of CCA(1,2).This data-supported approach developed by consensus of an expert panel,provides guidance statements based on analytical review of the relevant literature.

关 键 词：American Association for the Study of Liver Diseases(AASLD) GUIDELINES primary sclerosing cholangitis(PSC) liver cancer biliary cancer 

分 类 号：R735.8[医药卫生—肿瘤]